Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Aurelie Olivier"'
Autor:
Pierre-François Laterre, Stephan Witte, Jean-Marie Grouin, Simon Lambden, Bruno Francois, Sebastien Gibot, Marc Derive, Aurelie Olivier, Valerie Cuvier, Jean Jacques Garaud, Margarita Salcedo-Magguilli, Mitchell Levy
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction Septic shock is the subgroup of patients with sepsis, which presents as vasopressor dependence, an elevated blood lactate concentration and is associated with a mortality of at least 30%. Expression of the triggering receptor expressed o
Externí odkaz:
https://doaj.org/article/9b17e8be3e3443cebf020fb85a967645
Autor:
Selidji T Agnandji, Rolf Fendel, Michaël Mestré, Michel Janssens, Johan Vekemans, Jana Held, Ferdinand Gnansounou, Sonja Haertle, Isabel von Glasenapp, Sunny Oyakhirome, Ludovic Mewono, Philippe Moris, Marc Lievens, Marie-Ange Demoitie, Patrice M Dubois, Tonya Villafana, Erik Jongert, Aurelie Olivier, Joe Cohen, Meral Esen, Peter G Kremsner, Bertrand Lell, Benjamin Mordmüller
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e18559 (2011)
The recombinant circumsporozoite protein (CS) based vaccine, RTS,S, confers protection against Plasmodium falciparum infection in controlled challenge trials and in field studies. The RTS,S recombinant antigen has been formulated with two adjuvant sy
Externí odkaz:
https://doaj.org/article/15c7ade9e728478f8dac448f92278a4d
Autor:
Simon Lambden, Jean-Marie Grouin, Jean Jacques Garaud, Aurelie Olivier, Lucie Jolly, Marc Derive, Valerie Cuvier, Margarita Salcedo-Magguilli
Background:One of main new avenue of exploration in critical care medicine is the development of personalized medicine approaches to better determine which therapy provides the optimal risk/benefit ratio for subgroups of septic shock patients present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c21560c02c97ba2608eb1e1a67452da7
https://doi.org/10.21203/rs.3.rs-1181242/v1
https://doi.org/10.21203/rs.3.rs-1181242/v1
Autor:
Jean-Jacques Garaud, Marc Derive, Xavier Wittebole, François Vandenhende, Thierry Dugernier, Valerie Cuvier, Peter Pickkers, Stephan Witte, Miguel Angel Gomez Sanchez, Margarita Salcedo-Magguilli, Aurelie Olivier, Bruno François, Jean-Paul Mira, Ricard Ferrer, Pierre-François Laterre, Sébastien Gibot
Publikováno v:
Intensive Care Medicine, 46, 7, pp. 1425-1437
Intensive Care Medicine, 46, 1425-1437
Intensive Care Medicine, 46, 1425-1437
Contains fulltext : 225478.pdf (Publisher’s version ) (Closed access) PURPOSE: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interactions, restored vascular function, and improved survival, in animal septic sho
Autor:
Simon Lambden, Pierre-François Laterre, Marc Derive, Bruno François, Margarita Salcedo-Magguilli, Sébastien Gibot, Aurelie Olivier, Valerie Cuvier, Mitchell M. Levy, Jean Jacques Garaud, Stephan Witte, Jean-Marie Grouin
Publikováno v:
BMJ Open
BMJ Open, Vol 11, Iss 7 (2021)
BMJ open, Vol. 11, no.7, p. e042921 [1-6] (2021)
BMJ Open, Vol 11, Iss 7 (2021)
BMJ open, Vol. 11, no.7, p. e042921 [1-6] (2021)
IntroductionSeptic shock is the subgroup of patients with sepsis, which presents as vasopressor dependence, an elevated blood lactate concentration and is associated with a mortality of at least 30%. Expression of the triggering receptor expressed on
Autor:
Murdo Ferguson, Alexander Murray, Lew Pliamm, Lars Rombo, Johan Sanmartin Berglund, Marie-Pierre David, Nathalie De Schrevel, Franck Maschino, Shady Kotb, Aurélie Olivier, Veronica Hulstrøm
Publikováno v:
Vaccine: X, Vol 18, Iss , Pp 100494- (2024)
Background: Previous phase 3 studies showed that the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory
Externí odkaz:
https://doaj.org/article/b9ce1a2d0402470d812844986a1b8347
Autor:
Margarita Salcedo-Magguilli, Valerie Cuvier, Jean-Jacques Garaud, Ulrike Lorch, Stephan Witte, Aurelie Olivier, Isabelle Delor, Marc Derive, Sébastien Gibot
Publikováno v:
British Journal of Clinical Pharmacology. 84:2270-2279
Aims The peptide nangibotide is the first clinical-stage agent targeting the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1) and is being investigated as a novel therapy for acute inflammatory disorders such as septic shock.
Autor:
Valerie, Cuvier, Ulrike, Lorch, Stephan, Witte, Aurelie, Olivier, Sebastien, Gibot, Isabelle, Delor, Jean-Jacques, Garaud, Marc, Derive, Margarita, Salcedo-Magguilli
Publikováno v:
British journal of clinical pharmacology. 84(10)
AIMS: The peptide nangibotide is the first clinical‐stage agent targeting the immunoreceptor TREM‐1 (triggering receptor expressed on myeloid cells‐1) and is being investigated as a novel therapy for acute inflammatory disorders such as septic
Autor:
Johanna Blondeau, Olivier Danos, Siobhan O. Burns, Sabine Charrier, Anne Galy, Aurelie Olivier, Gerben Bouma, Daniel Compagno, Khalil Seye, Laurence Jeanson-Leh, William Vainchenker, Adrian J. Thrasher
Publikováno v:
Molecular Therapy. 13:729-737
The Wiskott Aldrich syndrome protein (WASP) is a hematopoietic-specific cytoskeletal regulator that is necessary for induction of normal immunity. In the context of effective gene therapy for WAS, cellular models of human WASP deficiency are importan
Autor:
John Lusingu, Ally Olotu, Amanda Leach, Marc Lievens, Johan Vekemans, Aurélie Olivier, Sarah Benns, Raimos Olomi, Salum Msham, Trudie Lang, Jayne Gould, Karin Hallez, Yolanda Guerra, Patricia Njuguna, Ken O Awuondo, Anangisye Malabeja, Omar Abdul, Samwel Gesase, Denise Dekker, Lincoln Malle, Sadiki Ismael, Neema Mturi, Chris J Drakeley, Barbara Savarese, Tonya Villafana, W Ripley Ballou, Joe Cohen, Eleanor M Riley, Martha M Lemnge, Kevin Marsh, Philip Bejon, Lorenz von Seidlein
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e14090 (2010)
The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-c
Externí odkaz:
https://doaj.org/article/5d6738e53a6c48248ce1123b1eec70c5